Board of Trustees of Univ. of Illinois files patent infringement action against Aurobindo involving generic versions of Prezista®
Clients Board of Trustees of the University of Illinois
Jones Day is representing the Board of Trustees of the University of Illinois in a patent infringement action against Aurobindo Pharma USA, Inc. relating to the defendant’s submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of Prezista® (darunavir), a market-leading protease inhibitor. The Firm is working closely with the United States, which co-owns the patent-in-suit, and with our licensee Janssen Products, L.P., which markets Prezista® (darunavir).
US Department of Health and Human Services et al. v. Aurobindo Pharma USA Inc., No. 3-17-cv-06911 (D.N.J.)